|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
MXPA01011279A
(es)
|
1999-05-07 |
2002-07-02 |
Genentech Inc |
Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
|
|
IL146508A0
(en)
|
1999-06-01 |
2002-07-25 |
Biogen Inc |
A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
|
|
CN1981868A
(zh)
|
2000-03-31 |
2007-06-20 |
拜奥根Idec公司 |
抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
|
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
|
CA2411102A1
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
JP5155502B2
(ja)
*
|
2000-06-20 |
2013-03-06 |
雪印メグミルク株式会社 |
鉄含有タンパク質組成物
|
|
US8632778B2
(en)
|
2000-08-11 |
2014-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized anti-interleukin-6 antibody-containing preparations
|
|
JP2002075937A
(ja)
|
2000-08-30 |
2002-03-15 |
Nitto Denko Corp |
半導体ウエハの加工方法
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
IL157946A0
(en)
|
2001-04-02 |
2004-03-28 |
Genentech Inc |
Combination therapy
|
|
GEP20074252B
(en)
|
2001-04-13 |
2007-12-10 |
Biogen Idec Inc |
Antibodies to vla-1
|
|
JP5052736B2
(ja)
*
|
2001-05-30 |
2012-10-17 |
中外製薬株式会社 |
タンパク質製剤
|
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
KR100968664B1
(ko)
|
2001-08-27 |
2010-07-06 |
제넨테크, 인크. |
항체 발현 및 조립을 위한 시스템
|
|
JP5290489B2
(ja)
*
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Ｉｇｇ抗体の安定な液体医薬製剤
|
|
AU2003211990A1
(en)
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
SI2371392T1
(sl)
|
2002-05-02 |
2015-10-30 |
Wyeth Holdings Llc |
Konjugati derivat-nosilec kaliheamicina
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
EP3263596A1
(en)
|
2002-12-16 |
2018-01-03 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
RU2358763C2
(ru)
|
2003-02-10 |
2009-06-20 |
Элан Фармасьютикалз, Инк. |
Композиции иммуноглобулина и способ их получения
|
|
EP2062916A3
(en)
|
2003-04-09 |
2009-08-19 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
|
|
CA2525251C
(en)
|
2003-05-09 |
2015-10-27 |
Duke University |
Cd20-specific antibodies and methods employing same
|
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
PL1631313T3
(pl)
|
2003-06-05 |
2015-08-31 |
Genentech Inc |
Terapia skojarzona zaburzeń z komórek B
|
|
EP1844815B1
(en)
|
2003-11-04 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
|
|
EP1680141B8
(en)
|
2003-11-04 |
2011-01-12 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
|
|
PT1694360E
(pt)
|
2003-11-04 |
2010-12-13 |
Novartis Vaccines & Diagnostic |
Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
|
|
CA2544951A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
|
|
ATE474598T1
(de)
|
2003-11-04 |
2010-08-15 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
WO2005063291A1
(ja)
*
|
2003-12-25 |
2005-07-14 |
Kirin Beer Kabushiki Kaisha |
抗体を含有する安定な水性医薬製剤
|
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
|
TW201422238A
(zh)
|
2004-06-04 |
2014-06-16 |
Genentech Inc |
Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
|
|
PL1776384T3
(pl)
|
2004-08-04 |
2013-10-31 |
Mentrik Biotech Llc |
WARIANTY REGIONÓW Fc
|
|
TW200621282A
(en)
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
TW200636066A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
BRPI0606867A2
(pt)
*
|
2005-01-28 |
2009-07-21 |
Wyeth Corp |
formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
|
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
EP1871806A2
(en)
*
|
2005-03-08 |
2008-01-02 |
Pharmacia & Upjohn Company LLC |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
|
ATE460672T1
(de)
|
2005-05-20 |
2010-03-15 |
Genentech Inc |
Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
|
|
NZ563580A
(en)
*
|
2005-06-07 |
2010-09-30 |
Esbatech An Alcon Biomedical R |
Stable and soluble antibodies inhibiting TNFaplha
|
|
JP2009502936A
(ja)
|
2005-07-25 |
2009-01-29 |
トルビオン ファーマシューティカルズ， インコーポレイテッド |
Ｃｄ２０特異的結合分子の単一投与量
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
CA2619298C
(en)
|
2005-08-26 |
2017-07-04 |
Glycart Biotechnology Ag |
Modified antigen binding molecules with altered cell signaling activity
|
|
AU2006296399B2
(en)
|
2005-09-30 |
2011-01-20 |
Medimmune Limited |
Interleukin-13 antibody composition
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
WO2007062090A2
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
HRP20150884T1
(hr)
|
2006-03-21 |
2015-09-25 |
Genentech, Inc. |
Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
|
|
WO2007110339A1
(en)
*
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-igf-1r human monoclonal antibody formulation
|
|
KR20140071452A
(ko)
|
2006-04-05 |
2014-06-11 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
MX2008014793A
(es)
|
2006-05-25 |
2008-12-02 |
Biogen Idec Inc |
Metodos para tratar la apoplejia.
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
CA2674608A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
CN104524567A
(zh)
|
2007-01-16 |
2015-04-22 |
阿布维公司 |
用于治疗银屑病的方法
|
|
CA2681752A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human 1l-12 antibodies
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
|
EP2167127A1
(en)
*
|
2007-07-10 |
2010-03-31 |
F. Hoffmann-Roche AG |
Novel formulation
|
|
PT2182983E
(pt)
|
2007-07-27 |
2014-09-01 |
Janssen Alzheimer Immunotherap |
Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
|
|
EP2200631A1
(en)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
JP2011503036A
(ja)
*
|
2007-11-12 |
2011-01-27 |
アレス トレーディング ソシエテ アノニム |
再発性多発性硬化症治療のためのｔａｃｉ−免疫グロブリン融合タンパク質
|
|
WO2009062960A1
(en)
*
|
2007-11-12 |
2009-05-22 |
Ares Trading S.A. |
Formulations for taci-immunoglobulin fusion proteins
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
KR101247418B1
(ko)
*
|
2007-12-21 |
2013-03-25 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
ES2382058T3
(es)
|
2008-01-17 |
2012-06-04 |
Philogen S.P.A. |
Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
|
PE20110302A1
(es)
*
|
2008-09-19 |
2011-05-21 |
Hoffmann La Roche |
Formulacion farmaceutica de un anticuerpo contra p-selectina
|
|
CN102256618A
(zh)
|
2008-10-17 |
2011-11-23 |
赛诺菲-安万特德国有限公司 |
胰岛素和glp-1激动剂的组合
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
MY173526A
(en)
|
2009-03-25 |
2020-01-31 |
Genentech Inc |
Novel anti-?5?1 antibodies and uses thereof
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
PL2451437T3
(pl)
|
2009-07-06 |
2017-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Wodne preparaty insuliny zawierające metioninę
|
|
ES2543095T3
(es)
|
2009-07-10 |
2015-08-14 |
Innate Pharma |
Agentes de unión a TLR3
|
|
CN104059955A
(zh)
|
2009-08-11 |
2014-09-24 |
弗·哈夫曼-拉罗切有限公司 |
在无谷氨酰胺的细胞培养基中的蛋白质生产
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
DK2483289T4
(da)
|
2009-10-02 |
2025-05-19 |
Biogen Ma Inc |
Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
|
|
TR201809460T4
(tr)
|
2009-11-13 |
2018-07-23 |
Sanofi Aventis Deutschland |
Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
|
|
NZ599847A
(en)
|
2009-11-13 |
2013-09-27 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
|
CN103108658B
(zh)
*
|
2010-07-02 |
2015-08-19 |
米迪缪尼有限公司 |
抗体制剂
|
|
JOP20190250A1
(ar)
*
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
|
FR2962908A1
(fr)
|
2010-07-20 |
2012-01-27 |
Lfb Biotechnologies |
Formulation d'anticorps anti-cd20
|
|
WO2012028172A1
(en)
|
2010-08-30 |
2012-03-08 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
BR112013008366B1
(pt)
*
|
2010-10-06 |
2022-02-08 |
Regeneron Pharmaceuticals, Inc |
Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
|
WO2012095432A2
(en)
|
2011-01-12 |
2012-07-19 |
Innate Pharma |
Tlr3 binding agents
|
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
DK2707383T3
(en)
|
2011-05-13 |
2018-07-23 |
Biogen Ma Inc |
PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULPHIDE BINDINGS
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
SG10201604104PA
(en)
|
2011-10-25 |
2016-07-28 |
Prothena Therapeutics Ltd |
Antibody formulations and methods
|
|
JP2013147471A
(ja)
*
|
2012-01-23 |
2013-08-01 |
Venture Bank Inc |
ダチョウ抗体水溶液
|
|
AU2013212587B2
(en)
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
CA2864539C
(en)
|
2012-02-16 |
2022-06-07 |
Santarus, Inc. |
Antibody formulations
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
EP2855527B1
(en)
|
2012-05-31 |
2018-08-01 |
Innate Pharma |
Tlr3 binding agents
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
WO2014039903A2
(en)
|
2012-09-07 |
2014-03-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of adalimumab
|
|
PL2934582T3
(pl)
*
|
2012-12-21 |
2020-08-10 |
Ichnos Sciences SA |
Formulacja przeciwciała anty-her2
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
EP2805730A1
(en)
|
2013-05-21 |
2014-11-26 |
Bergen Teknologioverforing AS |
Nitric oxide donor for the treatment of chronic fatigue syndrome
|
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
EP3062780A1
(en)
|
2013-11-01 |
2016-09-07 |
Bergen Teknologioverføring AS |
Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
|
|
JP2014062100A
(ja)
*
|
2013-11-05 |
2014-04-10 |
Glaxosmithkline Llc |
抗体処方
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
KR102372245B1
(ko)
|
2013-11-21 |
2022-03-08 |
젠맵 에이/에스 |
항체-약물 접합체 동결건조 제제
|
|
JP6723921B2
(ja)
|
2014-01-09 |
2020-07-15 |
サノフイＳａｎｏｆｉ |
インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
|
|
US9895423B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
|
CN105960249B
(zh)
|
2014-01-09 |
2021-03-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
|
KR102366644B1
(ko)
|
2014-05-30 |
2022-02-22 |
상하이 헨리우스 바이오테크, 인크. |
항-표피 성장 인자 수용체 (egfr) 항체
|
|
US10562946B2
(en)
|
2014-06-20 |
2020-02-18 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
|
AU2015346444A1
(en)
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
PE20171622A1
(es)
|
2014-12-12 |
2017-11-02 |
Sanofi Aventis Deutschland |
Formulacion de relacion fija de insulina glargina/lixisenatida
|
|
US10894083B2
(en)
|
2015-01-28 |
2021-01-19 |
Pfizer Inc. |
Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
|
|
JP6247241B2
(ja)
*
|
2015-02-27 |
2017-12-13 |
ノバルティス アーゲー |
抗体処方
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
AU2016243026B2
(en)
|
2015-04-03 |
2022-03-31 |
Eureka Therapeutics, Inc. |
Constructs targeting AFP peptide/MHC complexes and uses thereof
|
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
|
MX391086B
(es)
|
2015-06-24 |
2025-03-21 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad diseñada.
|
|
EP3352760B1
(en)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
EP4732904A2
(en)
|
2015-10-06 |
2026-04-29 |
F. Hoffmann-La Roche AG |
Method for treating multiple sclerosis
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
SG11201805534TA
(en)
|
2016-01-13 |
2018-07-30 |
Genmab As |
Formulation for antibody and drug conjugate thereof
|
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
|
BR112018073133A2
(pt)
|
2016-05-10 |
2019-04-30 |
Genentech Inc |
métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
|
|
EP3509616A1
(en)
|
2016-09-09 |
2019-07-17 |
H. Hoffnabb-La Roche Ag |
Selective peptide inhibitors of frizzled
|
|
WO2018052818A1
(en)
|
2016-09-16 |
2018-03-22 |
Henlix, Inc. |
Anti-pd-1 antibodies
|
|
EP3541413A2
(en)
|
2016-11-21 |
2019-09-25 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
|
IL270138B2
(en)
|
2017-04-26 |
2025-08-01 |
Eureka Therapeutics Inc |
Structures that specifically recognize glypican 3 and their uses
|
|
CN110198739B
(zh)
*
|
2017-05-16 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
一种pd-l1抗体药物组合物及其用途
|
|
ES2933256T3
(es)
|
2017-08-08 |
2023-02-03 |
Hoffmann La Roche |
Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG
|
|
CA3093692A1
(en)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
SG11202012342WA
(en)
|
2018-06-18 |
2021-01-28 |
Eureka Therapeutics Inc |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
WO2020061374A1
(en)
|
2018-09-20 |
2020-03-26 |
Mandalmed, Inc. |
Methods and compositions for preventing, treating, and reversing liver fibrosis
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
MX2021005751A
(es)
|
2018-11-16 |
2021-10-01 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos contra mucina 16 y métodos de uso de los mismos.
|
|
WO2020108423A1
(en)
|
2018-11-27 |
2020-06-04 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
|
|
BR112021016198A2
(pt)
*
|
2019-03-08 |
2021-11-03 |
Boehringer Ingelheim Int |
Formulações de anticorpo anti-il-36r
|
|
RU2754760C2
(ru)
*
|
2019-04-02 |
2021-09-07 |
Закрытое Акционерное Общество "Биокад" |
Водная фармацевтическая композиция анти-il17a антитела и ее применение
|
|
AU2020311511B2
(en)
|
2019-07-09 |
2024-08-29 |
Beijing Solobio Genetechnology Co., Ltd. |
Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
AU2020339737A1
(en)
|
2019-08-30 |
2022-03-17 |
Vestlandets Innovasjonsselskap As |
Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
|
|
CN116249548A
(zh)
|
2020-05-11 |
2023-06-09 |
詹森生物科技公司 |
用于治疗多发性骨髓瘤的方法
|
|
US20230220057A1
(en)
|
2020-05-27 |
2023-07-13 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
|
EP4182022A1
(en)
|
2020-07-17 |
2023-05-24 |
Boehringer Ingelheim International GmbH |
Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
|
|
WO2022036129A1
(en)
|
2020-08-14 |
2022-02-17 |
F. Hoffmann-La Roche Ag |
Methods for treating multiple sclerosis with ocrelizumab
|
|
US20250011448A1
(en)
|
2021-07-08 |
2025-01-09 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
|
IL312503A
(en)
|
2021-11-03 |
2024-07-01 |
Janssen Biotech Inc |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
AU2022383848A1
(en)
*
|
2021-11-10 |
2024-06-27 |
Janssen Biotech, Inc. |
Stable formulations comprising a bispecific bcma/cd3 antibody
|
|
KR20240102971A
(ko)
|
2021-11-16 |
2024-07-03 |
제넨테크, 인크. |
모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
|
|
US20250066458A1
(en)
|
2021-12-06 |
2025-02-27 |
Beijing Solobio Genetechnology Co., Ltd. |
Bispecific Antibodies Specifically Binding to Klebsiella Pneumoniae O2 Antigen and O1 Antigen and Compositions Thereof
|
|
WO2023116574A1
(zh)
*
|
2021-12-22 |
2023-06-29 |
舒泰神（北京）生物制药股份有限公司 |
一种分离的抗C5a抗体及其制剂与应用
|
|
CN119095873A
(zh)
|
2022-03-14 |
2024-12-06 |
拉姆卡普生物伽马股份公司 |
用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合
|
|
US20250326828A1
(en)
|
2022-05-09 |
2025-10-23 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies Specifically Recognizing Gdf15 and Uses Thereof
|
|
US20260035464A1
(en)
|
2022-07-19 |
2026-02-05 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
|
CN119998321A
(zh)
|
2022-09-27 |
2025-05-13 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别light的抗体及其应用
|
|
WO2024083021A1
(zh)
|
2022-10-20 |
2024-04-25 |
北京三诺佳邑生物技术有限责任公司 |
特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
|
|
EP4725501A1
(en)
|
2023-06-09 |
2026-04-15 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibody specifically binding to masp3, and multi-specific antibody specifically binding to masp3 and masp2
|
|
EP4729546A1
(en)
|
2023-06-16 |
2026-04-22 |
Jiangsu BioJeTay Biotechnology Co., Ltd. |
Antibody specifically recognizing factor xiia and use thereof
|
|
IL325726A
(en)
|
2023-07-11 |
2026-03-01 |
Genentech Inc |
Compositions and methods for treating multiple sclerosis
|